Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis

Brain

Volumn 126, Issue 12, 2003, Pages 2638-2647

  Salama, Hassan H ^a,c   Hong, Jian ^a   Zang, Ying C Q ^a   El Mongui, Azza ^c   Zhang, Jingwu ^a,b  

^a Baylor Methodist Multiple Sclerosis Center   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

Copaxone; Cytokines; Glatiramer acetate; Multiple sclerosis; Serum reactive antibodies

Indexed keywords

ANTIBODY; CYTOKINE; GLATIRAMER; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE DURATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOREGULATION; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE SCLEROSIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIBODIES, BLOCKING; CELL DIVISION; CELL LINE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RETROSPECTIVE STUDIES; T-LYMPHOCYTES;

EID: 0344012038     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awg269     Document Type: Article

References (37)

1. Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer 1 induces T-cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1997; 94: 10821-6.
2. Aharoni R, Teitelbaum D, Sela M, Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 1998; 91: 135-46.
3. Aharoni R, Teitelbaum D, Leitner O, Meshorer A, Sela M, Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer I. Proc Natl Acad Sci USA 2000; 97: 711472-7.
4. Aharoni R, Meshorer A, Sela M, Arnon R. Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system. J Neuroimmunol 2002; 126: 58-68.
5. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J Interferon Cytokine Res 1998; 18: 345-50.
6. Ben-Nun A, Mendel I, Bakimer R, Fridkis-Hareli M, Teitelbaum D, Arnon R, et al. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J Neurol 1996; 243 (4 Suppl 1): S14-22.
7. Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Riven-Kreitman R, et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001; 115: 152-60.
8. Chabot S, Yong FP, Le DM, Metz LM, Myles T, Yong VW. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis. Mult Scler 2002; 8: 299-306.
9. Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with multiple sclerosis. Mult Scler 2001; 7: 209-19.
10. Chen M, Conway K, Johnson K, Martin R, Dhib-Jalbut S. Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci 2002; 201: 71-7.
11. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing multiple sclerosis. Neurology 2002; 59: 1507-17.
12. Comi G. Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001a; 49: 290-7.
13. Comi G, Filippi M, Wolinsky JS. The extension phase of the European-Canadian MRI study demonstrates a sustained effect of glatiramer acetate in patients with relapsing-remitting multiple sclerosis [abstract]. European/Canadian Glatiramer Acetate Study Group. Neurology 2001b; 56 (8 Suppl 3): A255.
14. European Study Group on Interferon β-1b in Secondary Progressive Multiple Sclerosis. Placebo controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
15. Farina C, Then Bergh F, Albrecht H, Meinl E, Yassouridis A, Neuhaus O, et al. Treatment of multiple sclerosis with Copaxone (COP). Elispot assay detects COP-induced interleukin-4 and interferon-γ response in blood cells. Brain 2001; 124: 705-19.
16. Farina C, Vargas V, Heydari N, Kumpfel T, Meinl E, Hohlfeld R. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J Neuroimmunol 2002; 123: 188-92.
17. Fridkis-Hareli M, Strominger JL. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol 1998; 160: 4386-97.
18. Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon OJ, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells-specificity and promiscuity. Proc Natl Acad Sci USA 1994; 91: 4872-6.
19. Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000; 55: 1704-14.
20. Herndon RM, Jacobs LD, Coats ME, Goodkin DE, Mass MK, Richert JR, et al. Results of an ongoing, open-label, safety-extension study of interferon β-1a (Avonex) treatment in multiple sclerosis. Int J MS Care [serial online]. Dec 1999; 2: 1-6. Available from http://mscare.com.
21. Hussien Y, Sanna A, Söderström M, Link H, Huang Y-M. Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosis. J Neuroimmunol 2001; 121: 102-10.
22. IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
23. IFNB Multiple Sclerosis Study Group and the University of British Columbia Multiple Sclerosis/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon β-1b: experience during the first three years. Neurology 1996; 47: 889-94.
24. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon β-1a therapy initiated during a first demyelinating event in multiple sclerosis. New Engl J Med 2000; 343: 898-904.
25. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76.
26. Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Ambrozak DR, et al. Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis. J Clin Invest 2002; 109: 641-9.
27. Li Q, Milo R, Panitch H, Swoveland P, Bever CT Jr. Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma. Eur J Pharmacol 1998; 342: 303-10.
28. Maron R, Slavin AJ, Hoffmann E, Komagata Y, Weiner HL. Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines. Int Immunol 2002; 14: 131-8.
29. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56: 702-86.
30. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, et al. Randomized, comparative study of interferon β-1a treatment regimens in multiple sclerosis. The EVIDENCE Trial. Neurology 2002; 59: 1496-1506.
31. PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
32. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing multiple sclerosis. Neurology 2001; 56: 1628-36.
33. Racke MK, Martin R, McFarland H, Fritz RB. Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation. J Neuroimmunol 1992; 37: 75-84.
34. Teitelbaum D, Milo R, Arnon R, Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 1992; 89: 137-41.
35. Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 1996; 64: 209-17.
36. Ure DR, Rodriguez M. Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J 2002; 16: 1260-2.
37. Wiesemann E, Klatt J, Sönmez D, Blasczyk R, Heidenreich F, Windhagen A. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naïve T-cells. J Neuroimmunol 2001; 119: 137-44.